Navigation Links
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
Date:8/5/2008

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose's dry powder inhaler (DPI) technology announced in March 2008. This milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose DPI technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )

As previously announced, Merck will fund development and commercialization of products that employ MicroDose's DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

"MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months" commented David Byron, Vice President of Research and Development, MicroDose. "Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration."

About the MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical trials. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries.

In addition to the collaboration with Merck, MicroDose's other partnerships include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose's QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the U.S. Department of Defense, in collaboration with the University of Pittsburgh. MicroDose has ongoing feasibility programs with other major pharmaceutical companies and is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap(TM) technology, in the

areas of diabetes, hypertension and hyperlipidemia. For more information visit us at http://www.microdose-tech.com


'/>"/>
SOURCE MicroDose Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2018)... ... November 16, 2018 , ... Florida Hospital, Championship Level ... the Title Sponsor of the 18th Annual Florida Hospital Bolt Run, Saturday, November 17, ... with the first-ever finisher’s circle inside AMALIE Arena just a few feet away from ...
(Date:11/16/2018)... ... 2018 , ... Mytonomy, a leader in virtual digital health ... the usability of and satisfaction with Mytonomy’s video-based microlearning platform among people living ... the 18th Annual Diabetes Technology Society Meeting, showed that patients were highly satisfied ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... is thrilled to announce the launch of its newly redesigned website. , ... the company's mission and products. The newly redesigned website will be regularly updated ...
Breaking Medicine Technology:
(Date:11/16/2018)... ... ... AP was selected in the Health Care 2 ($10-$30M) Category and will be ... Hyatt Regency Downtown Dallas along with other companies who have illustrated exceptional qualities during ... Annual Excellence in Construction National Level Competition through Associated Builders and Contractors, Inc (ABC). ...
(Date:11/16/2018)... , ... November 16, 2018 , ... Nutrex Research ... skin care product called Lipo-6 Defining Gel . Utilizing TopiSorbTM Technology, this gel ... Stubborn cellulite and fatty deposits have met their match. , Maximizing fat loss ...
(Date:11/16/2018)... NEW YORK (PRWEB) , ... November 16, 2018 ... ... academic medical center, announced today a historic agreement with Taikang Healthcare in China ... for Taikang’s Xianlin Drum Tower Hospital in Nanjing, the capital of Jiangsu Province ...
(Date:11/16/2018)... ... November 16, 2018 , ... The ... China Resources Microelectronics Limited (CR Micro) and China Resources Life Science Industry ... establishing two joint research centres for novel micro-electronic devices and precision medicine. ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... investment from Winnebago Seed Fund and additional investors including Wind River Financial, a ... forge a strategic partnership with Wind River to provide a range of solutions ...
Breaking Medicine News(10 mins):